These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22108791)

  • 21. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.
    Carpenter KM; McDowell D; Brooks DJ; Cheng WY; Levin FR
    Am J Addict; 2009; 18(1):53-64. PubMed ID: 19219666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bupropion in the treatment of major depressive disorder in real-life practice.
    Sennfelt DA; Marques da Silva MA; Tavares AP
    Clin Drug Investig; 2011 Oct; 31 Suppl 1():19-24. PubMed ID: 22015859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bupropion and other non-nicotine pharmacotherapies.
    Roddy E
    BMJ; 2004 Feb; 328(7438):509-11. PubMed ID: 14988194
    [No Abstract]   [Full Text] [Related]  

  • 24. [Acute psychosis after administration of bupropion hydrochloride (Zyban)].
    Neumann M; Livak V; Paul HW
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S140-1. PubMed ID: 15570532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rhabdomyolysis associated with bupropion use as a smoking cessation adjunct: review of the literature.
    Miladi A
    Mil Med; 2008 Oct; 173(10):1042-3. PubMed ID: 19160627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact.
    Mayo JL; Cahill GM; Lott RS
    Pharmacotherapy; 2005 Apr; 25(4):520-5. PubMed ID: 15977913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does bupropion have advantages over other medical therapies in the cessation of smoking?
    Tonstad S; Johnston JA
    Expert Opin Pharmacother; 2004 Apr; 5(4):727-34. PubMed ID: 15102559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability and safety of sustained-release bupropion in the management of smoking cessation.
    Aubin HJ
    Drugs; 2002; 62 Suppl 2():45-52. PubMed ID: 12109935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
    Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
    Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
    J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2001 Oct; 145(42):2054. PubMed ID: 11695106
    [No Abstract]   [Full Text] [Related]  

  • 33. Bupropion (amfebutamone): caution during pregnancy.
    Prescrire Int; 2005 Dec; 14(80):225. PubMed ID: 16400747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bupropion sustained release: a therapeutic overview.
    Davidson JR; Connor KM
    J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bupropion-induced acute dystonia.
    Detweiler MB; Harpold GJ
    Ann Pharmacother; 2002 Feb; 36(2):251-4. PubMed ID: 11847943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bupropion, a possible antidepressant without negative effects on alcohol relapse.
    Ballesta A; Orio L; Arco R; Vargas A; Romero-Sanchiz P; Nogueira-Arjona R; de Heras RG; Antón M; Ramírez-López M; Serrano A; Pavón FJ; de Fonseca FR; Suárez J; Alen F
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):756-765. PubMed ID: 31064683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bupropion: efficacy and safety in the treatment of depression.
    Saiz Ruiz J; Gibert J; Gutiérrez Fraile M; Bobes J; Vallejo J; Iglesias C; Iriarte V
    Actas Esp Psiquiatr; 2011; 39 Suppl 1():1-25. PubMed ID: 22983817
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response.
    Ott GE; Rao U; Lin KM; Gertsik L; Poland RE
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):275-81. PubMed ID: 15122973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bupropion extended-release for depressive disorders.
    Jefferson JW
    Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.